Results 301 to 310 of about 6,463,095 (311)

Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer

Lung Cancer, 2013
Massimo Di Maio, Katsuyuki Hotta, Christian Dr. Manegold   +2 more
exaly  

Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): a multicenter, double-blind, prospective trial†

Annals of Oncology, 2013
Z M Shao, Z M Shao
exaly  

Pricing a Year of Progression-Free Survival

JAMA Dermatology, 2019
Sarah S P, DiMagno, Ezekiel J, Emanuel
openaire   +2 more sources

Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL Free

Blood, 2014
Jeanette K Doorduijn, Jan Walewski, Shulamiet Wittebol   +2 more
exaly  

Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials

Clinical Breast Cancer, 2018
Yinli Yang, Ling Li
exaly  

Data support longer recurrence-free survival with nivolumab than with ipilimumab for stage III or IV melanoma

Ca-A Cancer Journal for Clinicians
Carrie Printz
exaly  

Adding carboplatin to sequential taxane–anthracycline neoadjuvant chemotherapy shows improved event-free and overall survival benefits in premenopausal women with triple-negative breast cancer

Ca-A Cancer Journal for Clinicians
Carrie Printz
exaly  

Progression Free Survival and Overall Survival in NADIM II Study

2022
Provencio, M, Serna, R, Nadal, E, Larriba, JLG, Martinez-Marti, A, Bernabe, R, Bosch-Barrera, J, Benito, CG, Calvo, V, Insa, A, Ponce, S, Reguart, N, De Castro, J, Massuti, B, Palmero, R, de la Rosa, CA, Mosquera, J, Cobo, M, Aguilar, A, Vivanco, GL, Camps, C, Trancho, FH, Castro, RL, Moran, T, Barneto, I, Rodriguez-Abreu, D, Romero, A   +26 more
openaire   +1 more source

Correlation between progression-free and overall survival in patients with Hodgkin lymphoma: a comprehensive analysis of individual patient data from randomized German Hodgkin Study Group (GHSG) trials☆

Annals of Oncology
Paul J Bröckelmann, Justin Ferdinandus, Karolin Behringer   +2 more
exaly  

Osimertinib improves progression-free survival in NSCLC

The Lancet Oncology, 2018
openaire   +1 more source